13:59:15 EDT Sat 04 Apr 2020
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

News for U:VRNA from 2019-04-04 to 2020-04-03 - 32 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2020-03-31 02:00U:VRNANews ReleaseVerona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD
2020-03-16 13:14U:VRNANews Release2019 Annual Report and Accounts  and  Notice of AGM
2020-02-27 02:00U:VRNANews ReleaseVerona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate Update
2020-02-21 02:00U:VRNANews ReleaseVerona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate Update
2020-02-14 02:00U:VRNANews ReleaseVerona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research
2020-02-03 02:00U:VRNANews ReleaseVerona Pharma Announces Senior Management Changes
2020-01-13 00:00U:VRNANews ReleaseVerona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy
2020-01-10 18:00U:VRNANews ReleaseVerona Pharma to Report 4 Week Phase 2b COPD Dose-ranging Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy
2020-01-07 02:00U:VRNANews ReleaseVerona Pharma Appoints David Moskowitz as  Vice President, Capital Markets Strategy & Investor Relations
2019-11-13 02:00U:VRNANews ReleaseVerona Pharma to Present at Jefferies 2019 London Healthcare Conference
2019-11-11 02:00U:VRNANews ReleaseVerona Pharma to Participate in Two Upcoming Institutional Investor Conferences in New York
2019-11-05 02:00U:VRNANews ReleaseVerona Pharma plc  Operational Update and Financial Results for the Three and Nine Months Ended September  30, 2019
2019-10-29 03:00U:VRNANews ReleaseVerona Pharma to Announce Financial Results for the Three and Nine Months Ended September 30, 2019 and Provide Clinical Development Update
2019-10-17 02:00U:VRNANews ReleaseVerona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPD
2019-10-15 02:00U:VRNANews ReleaseVerona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019
2019-09-19 02:00U:VRNANews ReleaseVerona Pharma to Present Phase 2 Data with Ensifentrine Dry Powder Inhaler Formulation in COPD at European Respiratory Society International Congress 2019
2019-09-03 02:00U:VRNANews ReleaseVerona Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference
2019-08-06 02:00U:VRNANews ReleaseVerona Pharma plc:  Operational Update and Financial Results for the Three and Six Months Ended June  30, 2019
2019-08-05 02:00U:VRNANews ReleaseVerona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD
2019-07-30 02:00U:VRNANews ReleaseVerona Pharma to Announce Financial Results for Second Quarter Ended June 30, 2019 and Provide Clinical Development Update
2019-07-24 02:00U:VRNANews ReleaseVerona Pharma to Attend BTIG Biotechnology Conference 2019 and Present at 2019 Wedbush PacGrow Healthcare Conference
2019-06-25 02:00U:VRNANews ReleaseVerona Pharma Strengthens its Clinical Team Ahead of Phase 3 Development of Ensifentrine
2019-06-04 02:00U:VRNANews ReleaseVerona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD
2019-05-30 02:00U:VRNANews ReleaseVerona Pharma to Present at Jefferies 2019 Global Healthcare Conference
2019-05-20 10:15U:VRNANews ReleaseVerona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
2019-05-07 02:00U:VRNANews ReleaseVerona Pharma plc  Operational Update and Financial Results for the Three Months Ended March  31, 2019
2019-05-07 02:00U:VRNANews ReleaseVerona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 Trials
2019-05-02 07:00U:VRNANews ReleaseVerona Pharma to Present Clinical Trial Data of Ensifentrine for COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
2019-05-01 02:00U:VRNANews ReleaseVerona Pharma plc  ("Verona" or the "Company")  Appointment of Nominated Adviser and UK Broker
2019-05-01 02:00U:VRNANews ReleaseVerona Pharma to Announce Financial Results for First Quarter Ended March 31, 2019 and Provide Clinical Development Update
2019-04-25 07:07U:VRNANews ReleaseVerona Pharma to Host Investor & Analyst R&D Forum in London  on May 8, 2019
2019-04-09 02:00U:VRNANews ReleaseVerona Pharma Granted Key EU Patent Related to Late-stage COPD Clinical Candidate Ensifentrine